Ophthalmology Deals Are Up 1100% in 2026 — Here's the Data

Twelve ophthalmology deals closed between March 6 and September 6, 2026 — up from exactly one in the prior six-month period, a +1100% increase. This is not statistical noise. It is the single largest period-over-period acceleration in any therapeutic area we track at Ambrosia this year, and it reflects a structural shift: Big Pharma has collectively decided that ophthalmology is no longer a niche play but a core pipeline priority, and they are paying accordingly.

The Data — Ophthalmology Deal Activity, Period over Period

The contrast is stark. For the six months ending March 2026, ophthalmology licensing was functionally dormant — a single transaction in a half-year. Then the dam broke. April alone saw three deals close in rapid succession. By mid-year, Biogen had written a $5.6B check. The velocity here matters as much as the volume: this wasn't a gradual build. It was a coordinated land grab.

What's Driving the Trend

Pipeline gaps are the primary catalyst. The major pharma companies chasing ophthalmology in 2026 — AbbVie, Biogen, J&J, Merck — share a common problem: aging or thin retinal portfolios with LOE exposure in the next 3–5 years. AbbVie's HUMIRA successor strategy has been well-documented, but less discussed is its need for durable ophthalmology assets beyond existing dry eye and uveitis franchises. The Aldeyra deal and the REGENXBIO partnership signal AbbVie is building a next-generation retinal platform from scratch. Biogen, meanwhile, has essentially exited its neurodegeneration-only identity with the Apellis transaction — a $5.6B bet that complement biology in geographic atrophy represents a multi-decade commercial opportunity.

Gene therapy maturation is the accelerant. Two of the twelve deals — REGENXBIO/AbbVie and MeiraGTx/J&J — are gene therapy transactions. This is not coincidence. AAV-based ocular gene therapies have moved past the proof-of-concept stage. The eye remains the most pharmacologically accessible organ for gene delivery: immune-privileged, small volume, directly observable. Regulatory clarity from the FDA on CMC and potency assays for ocular gene therapies has de-risked the modality enough for Big Pharma to step in. J&J's $130M upfront for MeiraGTx reflects confidence in the platform, not just a single asset.

The competitive dynamic is self-reinforcing. Once Merck moved on EyeBio in early April, it triggered a cascade. BD teams at competing companies saw the signal and accelerated their own timelines. We have seen this pattern before — oncology ADCs in 2023, obesity in 2024 — but rarely at this speed. When four top-10 pharma companies enter the same TA within 90 days, the remaining players face a simple choice: pay up now or get priced out. That dynamic drove deal volume from single digits to double digits in a quarter.

Notable Deals

Apellis/Biogen ($5.6B) is the headline transaction and arguably the defining ophthalmology deal of the decade. Biogen acquired the entire Apellis complement franchise, anchored by SYFOVRE for geographic atrophy. At $5.6B total deal value with no contingent milestones, this is a clean premium-to-market acquisition — Biogen paid for commercial-stage certainty. The implied revenue multiple suggests Biogen is modeling GA as a $3B+ peak-revenue opportunity, which requires significant market expansion beyond current penetration rates. Bold, but defensible if treatment intervals improve.

MeiraGTx/J&J ($130M upfront) is the deal that should command the most attention from biotech founders. J&J paid $130M upfront for a gene therapy platform with clinical-stage assets in inherited retinal diseases. For a company with MeiraGTx's market cap at the time, that upfront represented transformational non-dilutive capital. This deal sets a new benchmark for ophthalmology gene therapy licensing in 2026 — particularly for platforms rather than single assets.

AbbVie's two-deal strategy — Aldeyra in April, REGENXBIO in June — deserves attention as a pattern. AbbVie is not making a single bet. It is constructing a diversified ophthalmology pipeline across modalities (small molecule via Aldeyra, gene therapy via REGENXBIO) and indications (inflammation, retinal degeneration). This is the kind of programmatic BD approach that signals sustained commitment to a therapeutic area, not opportunistic deal-making.

EyeBio/Merck was the first mover in April and likely catalyzed the broader wave. Merck's interest in ophthalmology had been telegraphed through its earlier-stage internal programs, but the EyeBio deal confirmed it was willing to acquire externally. For the rest of the market, that was the starting gun.

What This Means for BD Teams Right Now

If you are selling ophthalmology assets, you are in the strongest negotiating position this therapeutic area has seen in a decade. The data is unambiguous: five of the top fifteen global pharma companies executed ophthalmology deals in a single quarter. Demand is outstripping supply of quality clinical-stage assets. Use this. Upfront-to-TDV ratios in this window favor licensors, and the MeiraGTx deal demonstrates that platforms — not just lead assets — are commanding premium economics.

Tactically, BD teams at ophthalmology biotechs should be running competitive processes now, not waiting for Phase 2 readouts. The buyers are in-market today. J&J, AbbVie, Biogen, and Merck have all shown their hands. The remaining top-10 players — Roche, Novartis (already strong in ophthalmology), Pfizer, Lilly — are the next logical entrants. A well-structured dual-track process (IPO vs. licensing) gives you maximum leverage. Use Solidus to model your deal value against the current ophthalmology benchmarks before entering negotiations.

If you are buying, speed is your only advantage. Waiting for de-risking events (data readouts, regulatory milestones) will cost you. The Apellis deal proves that acquirers are willing to pay commercial-stage multiples to avoid competitive auctions. For earlier-stage assets, the window to lock in reasonable upfronts is closing. Every month of delay compresses your negotiating leverage as more buyers enter the space.

Deal structures are shifting accordingly. We are seeing higher upfront-to-TDV ratios, shorter milestone ladders, and more aggressive opt-in timelines. Royalty stacking on gene therapies remains a friction point — buyers want clean IP stacks, and licensors with freedom-to-operate on their AAV capsids are commanding premiums. If your asset has capsid IP encumbrances, address them before you go to market.

Benchmark your deal against current market rates using the Ambrosia calculator — ophthalmology deal economics have shifted dramatically in 2026, and last year's comps are no longer reliable references.